The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

A controversial anti-obesity drug is set to become more widely available on the NHS. Orlistat, otherwise known as Xenical, has been prescribed free to some obese patients for the past two years.

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

The rapid growth of the anti-obesity drug market is primarily fueled by a handful of medications that have redefined the landscape of obesity treatment. Each drug has unique attributes that contribute ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly ... giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.